Suvorexant for insomnia in patients with psychiatric disorder: A 1-week, open-label study.

Taro KishiKenji SakumaMakoto OkuyaKohei NinomiyaKazuto OyaMomoko KuboYuki MatsuiIkuo NomuraYuji OkuyamaShinji MatsunagaNakao Iwata

Published in: Neuropsychopharmacology reports (2019)

Suvorexant was beneficial for the treatment of insomnia in people with psychiatric disorders. However, this study was of short duration and included only a relatively small number of patients. A larger, long-term study is needed to investigate the efficacy and safety of suvorexant for insomnia in people with psychiatric disorders.

Keyphrases

open label
end stage renal disease
clinical trial
squamous cell carcinoma
ejection fraction
sleep quality
physical activity
peritoneal dialysis